Kai W. Wucherpfennig

Dana-Farber Cancer Institute — United States

Immunology and Microbiology · Life Sciences

99h-index44.9kcitations624works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(188), CAR-T cell therapy research(163), Cancer Immunotherapy and Biomarkers(156), Immunotherapy and Immune Responses(150), T-cell and B-cell Immunology(132)

Publications623 total

Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial
Cell·2026Open Access
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S10 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S11 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Table S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Supplementary Fig. S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
2025Open Access
Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma
Blood·2025
Functional investigation into NK cells identifies salt-inducible kinases as novel therapeutic targets against NK malignancies
Blood·2025Open Access
244 CARM1 knockout enhances anti-MICA/B CAR-T cell efficacy against large solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
264 Next-generation off-the-shelf CAR T cell targeting pan-tumor antigen MICA/B and engineered with immune evasion enables treatment across solid tumors without the need for conditioning chemotherapy
Regular and Young Investigator Award Abstracts·2025Open Access
CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success
Cell·2025· 2 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Adrienne Luoma(12), Aviv Regev(6), Orit Rozenblatt–Rosen(6), Jason W. Pyrdol(6), Itay Tirosh(5), Mario L. Suvà(5), Patrick A. Ott(4), Sachet A. Shukla(4), Charles H. Yoon(4), Scott J. Rodig(4), Nathan D. Mathewson(4), Guo‐Cheng Yuan(4), Vijay K. Kuchroo(4), Shannon J. Turley(4), David A. Hafler(4), Peng Jiang(3), Gordon J. Freeman(3), Zhuting Hu(3), Derin B. Keskin(3), Jing Sun(3)